Literature DB >> 25949922

Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.

Yusuke Sato1, Kanako Shimizu1, Jun Shinga1, Michihiro Hidaka2, Fumio Kawano2, Kazuhiro Kakimi3, Satoru Yamasaki1, Miki Asakura1, Shin-Ichiro Fujii1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population with the ability to suppress immune responses and are currently classified into three distinct MDSC subsets: monocytic, granulocytic and non-monocytic, and non-granulocytic MDSCs. Although NK cells provide an important first-line defense against newly transformed cancer cells, it is unknown whether NK cells can regulate MDSC populations in the context of cancer. In this study, we initially found that the frequency of MDSCs in non-Hodgkin lymphoma (NHL) patients was increased and inversely correlated with that of NK cells, but not that of T cells. To investigate the regulation of MDSC subsets by NK cells, we used an EL4 murine lymphoma model and found the non-monocytic and non-granulocytic MDSC subset, i.e., Gr1+CD11b+Ly6GmedLy6Cmed MDSC, is increased after NK cell depletion. The MDSC population that expresses MHC class II, CD80, CD124, and CCR2 is regulated mainly by CD27+CD11b+NK cells. In addition, this MDSC subset produces some immunosuppressive cytokines, including IL-10 but not nitric oxide (NO) or arginase. We also examined two subsets of MDSCs (CD14+HLA-DR- and CD14- HLA-DR- MDSC) in NHL patients and found that higher IL-10-producing CD14+HLA-DR-MDSC subset can be seen in lymphoma patients with reduced NK cell frequency in peripheral blood. Our analyses of MDSCs in this study may enable a better understanding of how MDSCs manipulate the tumor microenvironment and are regulated by NK cells in patients with lymphoma.

Entities:  

Keywords:  DFS; GM-CSF, granulocyte macrophage colony-stimulating factor; HLA, Human Leukocyte Antigen; IL, interleukin; IL-10; LPS, Lipopolysaccharide; MDSC; MDSC, myeloid-derived suppressor cell; NHL, non-Hodgkin lymphoma; NK cells; NK, Natural killer cells; OS, overall survival; PBMC, peripheral blood mononucleated cell; TGFβ, transforming growth factor β; TNFα, tumor necrosis factor α; VEGF, vascular endothelial growth factor; disease-free survival; immunoregulation; malignant lymphoma

Year:  2015        PMID: 25949922      PMCID: PMC4404816          DOI: 10.1080/2162402X.2014.995541

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  53 in total

1.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

2.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 3.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

Review 4.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 5.  Myeloid-derived suppressor cell heterogeneity in human cancers.

Authors:  Samantha Solito; Ilaria Marigo; Laura Pinton; Vera Damuzzo; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Ann N Y Acad Sci       Date:  2014-06       Impact factor: 5.691

6.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.

Authors:  Kanako Shimizu; Takuya Mizuno; Jun Shinga; Miki Asakura; Kazuhiro Kakimi; Yasuyuki Ishii; Kenichi Masuda; Tomoji Maeda; Hidetoshi Sugahara; Yusuke Sato; Hirokazu Matsushita; Keigo Nishida; Kenichi Hanada; Jan Dorrie; Niels Schaft; Kara Bickham; Hisashi Koike; Tsuyoshi Ando; Ryozo Nagai; Shin-ichiro Fujii
Journal:  Cancer Res       Date:  2012-10-29       Impact factor: 12.701

8.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Authors:  Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

9.  Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1.

Authors:  V De Wilde; N Van Rompaey; M Hill; J F Lebrun; P Lemaître; F Lhommé; C Kubjak; B Vokaer; G Oldenhove; L M Charbonnier; M C Cuturi; M Goldman; A Le Moine
Journal:  Am J Transplant       Date:  2009-07-22       Impact factor: 8.086

10.  Cloned cell lines with natural killer activity. Specificity, function, and cell surface markers.

Authors:  G Dennert; G Yogeeswaran; S Yamagata
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 4.  What Inhibits Natural Killers' Performance in Tumour.

Authors:  Ines Papak; Elżbieta Chruściel; Katarzyna Dziubek; Małgorzata Kurkowiak; Zuzanna Urban-Wójciuk; Tomasz Marjański; Witold Rzyman; Natalia Marek-Trzonkowska
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 5.  MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Authors:  Chiara Cioccarelli; Barbara Molon
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 6.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 7.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

Review 8.  Premetastatic niche formation in the liver: emerging mechanisms and mouse models.

Authors:  Achim Krüger
Journal:  J Mol Med (Berl)       Date:  2015-09-24       Impact factor: 4.599

9.  Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients.

Authors:  Masato Kobayashi; Jin-Sung Chung; Muhammad Beg; Yull Arriaga; Udit Verma; Kevin Courtney; John Mansour; Barbara Haley; Saad Khan; Yutaka Horiuchi; Vijay Ramani; David Harker; Purva Gopal; Farshid Araghizadeh; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Clin Cancer Res       Date:  2018-07-26       Impact factor: 12.531

10.  The role of immune cell subpopulations in the growth and rejection of TC-1/A9 tumors in novel mouse strains differing in the H2-D haplotype and NKC domain.

Authors:  Marie Indrová; Joanna Rossowska; Elzbieta Pajtasz-Piasecka; Romana Mikyšková; Jan Richter; Jozef Rosina; Radislav Sedlacek; Anna Fišerová
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.